^
3d
Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing. (PubMed, Indian J Med Res)
Fusion transcript analysis identified 91 recurrent fusions, including novel partners with ERBB2, MED1, and CDK12, suggesting the possibility of unique molecular events. Interpretation and conclusions This study demonstrates that Indian breast cancer patients exhibit molecular subtypes and actionable mutations comparable to Caucasian cohorts.
Review • Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK12 (Cyclin dependent kinase 12) • MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase)
|
HER-2 positive • TP53 mutation • BRCA2 mutation • ER positive • BRCA1 mutation • PIK3CA mutation • HER-2 expression • PTEN mutation • FGFR2 mutation • AKT1 mutation
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
18d
New P1/2 trial • First-in-human
|
PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
|
EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • AKT1 mutation
|
Tagrisso (osimertinib) • Truqap (capivasertib)
1m
Unveiling the potential of apigenin and kaempferol against colon cancer: an integrated network pharmacology and docking approach. (PubMed, Front Bioinform)
Apigenin and kaempferol showed potential as dual-targeting agents for colon cancer therapy. Cell culture and animal model studies in future are warranted to substantiate the mechanistic roles in tumor suppression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • JUN (Jun proto-oncogene)
|
AKT1 mutation
1m
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations (clinicaltrials.gov)
P1, N=134, Active, not recruiting, Atavistik Bio, Inc | Recruiting --> Active, not recruiting
Enrollment closed • First-in-human
|
HER-2 (Human epidermal growth factor receptor 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
HER-2 negative • HER-2 mutation • AKT1 mutation
|
fulvestrant
2ms
Precision oncology in Bulgaria: a prospective study of metastatic colorectal cancer patients. (PubMed, Cancer Treat Res Commun)
This study provides a regional molecular profile of advanced CRC in Bulgaria, highlighting a high prevalence of KRAS mutations and dMMR status, while underrepresentation of rare targetable alterations, likely due to limited use of broad molecular profiling. The association between stromal features and MMR status supports their potential role as surrogate markers in settings with constrained testing resources. Findings underscore the urgent need for equitable access to molecular diagnostics and targeted therapies to close the survival gap between Eastern and Western Europe.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • PIK3CA mutation • BRAF V600 • HER-2 mutation • AKT1 mutation
|
Ventana MMR RxDx Panel • TruSight Tumor 15 Assay
2ms
New P1/2 trial
|
PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
|
EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • PTEN mutation • AKT1 mutation
|
Tagrisso (osimertinib) • Truqap (capivasertib) • simmitinib (SYHA1817)
2ms
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer. (PubMed, Int J Mol Sci)
In external transcriptomic validation (TCGA-CRC), GSEA indicated enrichment of interferon/inflammatory programs in TIGIT-high tumors, while CD155-high tumors preferentially showed proliferation-related MYC/E2F/G2M signatures. Together, these findings support tumor-wide upregulation of the TIGIT/CD155 axis in CRC and suggest that TIGIT, more than CD155, tracks with MSI/BRAF-associated immune activation, providing a rationale for patient stratification in checkpoint-directed immunotherapy.
Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CSF1 (Colony stimulating factor 1) • PVR (PVR Cell Adhesion Molecule) • IL1R1 (Interleukin 1 receptor, type I)
|
BRAF mutation • PIK3CA mutation • BRAF wild-type • AKT1 mutation
3ms
A071401: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas (clinicaltrials.gov)
P2, N=124, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027
Trial primary completion date
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • PTCH1 (Patched 1) • CDK4 (Cyclin-dependent kinase 4) • NF2 (Neurofibromin 2) • SMO (Smoothened Frizzled Class Receptor) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3)
|
PIK3CA mutation • PTEN mutation • AKT1 mutation
|
Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098
3ms
Rare recurrent multiple pulmonary sclerosing pneumocytoma with sarcomatoid features: A case report and literature review. (PubMed, J Cancer Res Ther)
These features often create diagnostic challenges during preoperative biopsy, intraoperative frozen section analysis, and postoperative histopathological evaluation. Herein, we report a rare case of recurrent, multifocal PSP exhibiting sarcomatoid features and harboring a p.E17K mutation in the AKT1 gene.
Review • Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
AKT1 mutation
4ms
Trial suspension
|
AKT2 (V-akt murine thymoma viral oncogene homolog 2)
|
AKT1 mutation
|
paclitaxel • ipatasertib (RG7440)
4ms
Widespread Epistasis between Cancer Driver Mutations and Allele-Specific Copy Number Variations. (PubMed, bioRxiv)
Lung cancer patients carrying co-occurrences of somatic mutation-CNVs in TP53 and KRAS showed poorer survival than those carrying the same gene mutations. These findings reveal epistasis of cancer mutations and CNVs at an allelic resolution, suggesting specific genomic events to enhance patient stratification and therapeutic targeting.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • KRAS G12 • NRAS Q61 • AKT1 mutation • NRAS G12 • IDH1 R132